We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Merck Enters Obesity Space, Buys Rights to Hansoh's Oral GLP-1 Drug
Read MoreHide Full Article
To foray into the lucrative obesity market, Merck (MRK - Free Report) announced that it is in-licensing global rights to an investigational oral GLP-1 receptor agonist, HS-10535, from Chinese biotech Hansoh Pharma.
For the exclusive global rights to develop, manufacture and commercialize this pre-clinical candidate, Merck will make an upfront payment of $112 million to Hansoh Pharma, with the latter also being entitled to receive up to $1.9 billion in milestone payments and royalties on sales. Hansoh has an option to co-promote or solely commercialize HS-10535 in China.
For the deal, Merck will record a pre-tax charge of $112 million or 4 cents per share in the fourth quarter of 2024.
The GLP-1 segment is a very important class of drugs for multiple cardiometabolic diseases like diabetes and obesity and is gaining significant popularity. GLP-1 drugs work by mimicking the hormone GLP-1, resulting in weight loss, lowering hemoglobin A1c (HbA1c) and reducing cardiovascular risks.
Eli Lilly (LLY - Free Report) and Novo Nordisk (NVO - Free Report) are presently dominating the obesity market with their weekly GLP-1 injections, Zepbound and Wegovy, respectively. Lilly and Novo Nordisk also market their diabetes drugs, Mounjaro and Ozempic, off-label for weight loss.
Oral pills like HS-10535, if approved as weight loss drugs, can significantly improve patients’ convenience and potentially their costs.
Merck shares have declined 9.8% this year so far compared to the industry’s growth of 6.5%.
Image Source: Zacks Investment Research
Obesity Market is Heating Up
Obesity has become a global health problem as it can cause other diseases like heart disease, diabetes and stroke, leading to an exponential increase in demand for obesity medicines. Also, social media has somewhat hyped the benefits of these medications.
The obesity market is expected to expand to $100 billion by 2030, according to data from Goldman Sachs. All large drugmakers are looking to strengthen their presence in this market by expanding their existing obesity pipeline or acquiring smaller biotechs whose pipeline has novel obesity candidates.
Lilly is investing broadly in obesity and has 11 new molecules currently in clinical development. These include two late-stage candidates, orforglipron, an oral GLP-1 small molecule and retatrutide, a GGG tri-agonist and some mid-stage candidates, bimagrumab, eloralintide and mazdutide.
Novo Nordisk is also evaluating a once-daily oral formulation of Wegovy in late-stage studies.
Amgen and Viking Therapeutics (VKTX - Free Report) are also making rapid progress in the development of GLP-1-based candidates in their clinical pipeline.
Last month, Amgen announced 52-week top-line data from a phase II study on MariTide, its GLP-1 therapy for obesity. The data showed that MariTide led to approximately 20% average weight loss over 52 weeks without reaching a weight loss plateau.
Viking is developing its GIP/GLP-1 agonist VK2735 as a subcutaneous (SC) injection and an oral pill to treat obesity in a phase II and phase I study. VK2735 has demonstrated superior weight reduction capabilities in both clinical studies. VKTX shares dropped 18% on Wednesday in response to Merck’s obesity deal announcement. Merck was rumored to be the most likely acquirer of Viking.
Pfizer is developing danuglipron, an oral GLP-1R agonist for obesity, in a phase I study. Roche acquired Carmot Therapeutics in January and gained clinical-stage assets with best-in-class potential in obesity (CT-388 and CT-996). AstraZeneca also bought rights to AZD5004, a small-molecule oral GLP-1 receptor, from a Chinese biotech in November 2023.
Image: Bigstock
Merck Enters Obesity Space, Buys Rights to Hansoh's Oral GLP-1 Drug
To foray into the lucrative obesity market, Merck (MRK - Free Report) announced that it is in-licensing global rights to an investigational oral GLP-1 receptor agonist, HS-10535, from Chinese biotech Hansoh Pharma.
For the exclusive global rights to develop, manufacture and commercialize this pre-clinical candidate, Merck will make an upfront payment of $112 million to Hansoh Pharma, with the latter also being entitled to receive up to $1.9 billion in milestone payments and royalties on sales. Hansoh has an option to co-promote or solely commercialize HS-10535 in China.
For the deal, Merck will record a pre-tax charge of $112 million or 4 cents per share in the fourth quarter of 2024.
The GLP-1 segment is a very important class of drugs for multiple cardiometabolic diseases like diabetes and obesity and is gaining significant popularity. GLP-1 drugs work by mimicking the hormone GLP-1, resulting in weight loss, lowering hemoglobin A1c (HbA1c) and reducing cardiovascular risks.
Eli Lilly (LLY - Free Report) and Novo Nordisk (NVO - Free Report) are presently dominating the obesity market with their weekly GLP-1 injections, Zepbound and Wegovy, respectively. Lilly and Novo Nordisk also market their diabetes drugs, Mounjaro and Ozempic, off-label for weight loss.
Oral pills like HS-10535, if approved as weight loss drugs, can significantly improve patients’ convenience and potentially their costs.
Merck shares have declined 9.8% this year so far compared to the industry’s growth of 6.5%.
Image Source: Zacks Investment Research
Obesity Market is Heating Up
Obesity has become a global health problem as it can cause other diseases like heart disease, diabetes and stroke, leading to an exponential increase in demand for obesity medicines. Also, social media has somewhat hyped the benefits of these medications.
The obesity market is expected to expand to $100 billion by 2030, according to data from Goldman Sachs. All large drugmakers are looking to strengthen their presence in this market by expanding their existing obesity pipeline or acquiring smaller biotechs whose pipeline has novel obesity candidates.
Lilly is investing broadly in obesity and has 11 new molecules currently in clinical development. These include two late-stage candidates, orforglipron, an oral GLP-1 small molecule and retatrutide, a GGG tri-agonist and some mid-stage candidates, bimagrumab, eloralintide and mazdutide.
Novo Nordisk is also evaluating a once-daily oral formulation of Wegovy in late-stage studies.
Amgen and Viking Therapeutics (VKTX - Free Report) are also making rapid progress in the development of GLP-1-based candidates in their clinical pipeline.
Last month, Amgen announced 52-week top-line data from a phase II study on MariTide, its GLP-1 therapy for obesity. The data showed that MariTide led to approximately 20% average weight loss over 52 weeks without reaching a weight loss plateau.
Viking is developing its GIP/GLP-1 agonist VK2735 as a subcutaneous (SC) injection and an oral pill to treat obesity in a phase II and phase I study. VK2735 has demonstrated superior weight reduction capabilities in both clinical studies. VKTX shares dropped 18% on Wednesday in response to Merck’s obesity deal announcement. Merck was rumored to be the most likely acquirer of Viking.
Pfizer is developing danuglipron, an oral GLP-1R agonist for obesity, in a phase I study. Roche acquired Carmot Therapeutics in January and gained clinical-stage assets with best-in-class potential in obesity (CT-388 and CT-996). AstraZeneca also bought rights to AZD5004, a small-molecule oral GLP-1 receptor, from a Chinese biotech in November 2023.
Merck has a Zacks Rank #3 (Hold) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Merck & Co., Inc. Price and Consensus
Merck & Co., Inc. price-consensus-chart | Merck & Co., Inc. Quote